# Association of HLA Class-I and Inhibitory KIR Genotypes in Gabonese Patients Infected by Chikungunya or Dengue Type-2 Viruses

Caroline Petitdemange, Nadia Wauquier, Jean-Michel Jacquet, Ioannis Theodorou, Eric M. Leroy, Vincent Vieillard

► To cite this version:

Caroline Petitdemange, Nadia Wauquier, Jean-Michel Jacquet, Ioannis Theodorou, Eric M. Leroy, et al.. Association of HLA Class-I and Inhibitory KIR Genotypes in Gabonese Patients Infected by Chikungunya or Dengue Type-2 Viruses. PLoS ONE, 2014, 9 (9), pp.e108798. 10.1371/journal.pone.0108798. hal-01368411

HAL Id: hal-01368411

https://hal.sorbonne-universite.fr/hal-01368411v1

Submitted on 19 Sep 2016

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
# Association of HLA Class-I and Inhibitory KIR Genotypes in Gabonese Patients Infected by Chikungunya or Dengue Type-2 Viruses

Caroline Petitdemange<sup>1,2,3</sup>, Nadia Wauquier<sup>1,4</sup>, Jean-Michel Jacquet<sup>5</sup>, Ioannis Theodorou<sup>1,2,5</sup>, Eric Leroy<sup>3,6</sup>, Vincent Vieillard<sup>1,2,7*</sup>

1 Sorbonne Universités, UPMC, Univ Paris 06, CR7, CIMI-Paris, Paris, France, 2 INSERM, U1135, CIMI-Paris, Paris, France, 3 Centre International de Recherches Médicales de Franceville, Unité des maladies Emergentes, Franceville, Gabon, 4 Metabiota Inc., San Francisco, California, United States of America, 5 AP-HP Hôpital Pitié-Salpêtrière, Département d'Immunologie, Paris, France, 6 IRD, Maladies Infectieuses et Vecteurs: Ecologie, Génétique, Evolution et Contrôle, Montpellier, France, 7 CNRS, ERL8255, CIMI-Paris, Paris, France

<figure><img src="image_2.png" /></figure>

CrossMark

*click for updates*

## Abstract

**Background:** Natural killer (NK) cells provide defense in the early stages of the immune response against viral infections. Killer cell immunoglobulin-like receptors (KIR) expressed on the surface of NK cells play an important role in regulating NK cell response through recognition of human leukocyte antigen (HLA) class I molecules on target cells. Previous studies have shown that specific KIR/ligand combinations are associated with the outcome of several viral infectious diseases.

**Methods:** We investigated the impact of inhibitory and activating KIR and their HLA-class I ligand genotype on the susceptibility to Chikungunya virus (CHIKV) and Dengue virus (DENV2) infections. From April to July 2010 in Gabon, a large outbreak of CHIKV and DENV2 concomitantly occurred in two provinces of Gabon (Ogooué-Lolo and Haut-Ogooué). We performed the genotypic analysis of KIR in the combination with their cognate HLA-class I ligands in 73 CHIKV and 55 DENV2 adult cases, compared with 54 healthy individuals.

**Results:** We found in CHIV-infected patients that KIR2DL1 and KIR2DS5 are significantly increased and decreased respectively, as compared to DENV2⁺ patients and healthy donors. The combination of KIR2DL1 and its cognate HLA-C2 ligand was significantly associated with the susceptibility to CHIKV infection. In contrast, no other inhibitory KIR-HLA pairs showed an association with the two mosquito-borne arboviruses.

**Conclusion:** These observations are strongly suggestive that the NK cell repertoire shaped by the KIR2DL1:HLA-C2 interaction facilitate specific infection by CHIKV.

**Citation:** Petitdemange C, Wauquier N, Jacquet J-M, Theodorou I, Leroy E, et al. (2014) Association of HLA Class-I and Inhibitory KIR Genotypes in Gabonese Patients Infected by Chikungunya or Dengue Type-2 Viruses. PLoS ONE 9(9): e108798. doi:10.1371/journal.pone.0108798

**Editor:** Niklas K. Björkström, Karolinska Institutet, Sweden

**Received** March 13, 2014; **Accepted** September 2, 2014; **Published** September 29, 2014

**Copyright:** © 2014 Petitdemange et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability:** The authors confirm that all data underlying the findings are fully available without restriction. All data are included within the paper.

**Funding:** This study was funded in part by the Institut National de la Recherche Médicale (INSERM), and the Université Pierre et Marie Curie, Paris, France. Vincent Vieillard is a researcher from the Centre National de la Recherche Scientifique (CNRS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** Nadia Wauquier is consultant at Metabiota Inc. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. The remaining authors declare no conflicts of interest. All authors have contributed to, seen, and approved the final, revised version of the manuscript.

* Email: vincent.vieillard@upmc.fr

## Introduction

Chikungunya virus (CHIKV) and Dengue virus (DENV) are two mosquito-borne arboviruses transmitted by the *Aedes* genus. The diseases caused by these viruses have much in common in terms of symptoms, incubation period, clinical course, and symptomatic treatments. Both viruses have been recently proven responsible for major outbreaks leading to serious health and economical problems, and the rapid geographical expansion of their vector could potentially lead to a worldwide increased risk within non-immune populations [1,2]. However, unlike CHIKV, DENV strains are divided into four different serotypes (DENV1 to DENV4), which only confer short-term partial cross-protection against other strains, and contribute to the development of severe

forms of Dengue fever (Dengue haemorrhagic fever/Dengue shock syndrome) [3]. Through active surveillance of acute febrile syndrome in Gabon, CHIKV and serotype 2 DENV (DENV2) were detected between 2007 and 2010, and have caused together a large simultaneous outbreak centered on Franceville in southeast Gabon in 2010 [4].

Although natural killer (NK) cells hold a central role early after number of viral infections, not only for viral containment but also for timely and efficient induction of adaptive responses, their role in the control of CHIKV and DENV2 infections is still poorly documented [5,6]. NK cells are controlled by a combination of activating and inhibitory receptors, and the integration of signals induced upon ligation of these receptors determines whether they become activated. These receptors include the killer cell immu-
noglobulin-like receptors (KIR) that encode for a family of highly
polymorphic genes, and individual KIR haplotypes differ in
number and identity of genes [7]. Expression of KIR receptors is
very complex and controlled by a stochastic mechanism that shuts
off expression of some receptors and not others in individual cells
thereby allowing different NK cell clones to recognize different
targets [8]. It is therefore unlikely for two unrelated individuals to
share the same KIR genes or haplotypes and express the receptors.
The KIR receptors are type I integral membrane glycoproteins
that are usually expressed on the cell surface as monomers. The
KIR receptors are named according to the number (i.e. 2 or 3) of
Ig-like domains present in the extracellular region as well as the
length (i.e. L: long or S: short) of their cytoplasmic tails.
Functionally, KIR-L carry one or two tyrosine-based inhibition
motifs (ITIMs), which contribute to inhibitory signaling whereas,
KIR-S have a lysine residue in their trans-membrane domain that
is required for pairing with the tyrosine-based activation motif
(ITAM) - containing adaptor DAP12 [9]. The KIR family now
includes seven inhibitory KIRs and six activating KIRs, in
addition to KIR2DLA, which is an unusual activating member
of the KIR family with inhibitory potential. KIRs bind polymor-
phic major histocompatibility complex (MHC) class-I molecules.
For instance KIR2DL1/KIR2DS1 and KIR2DL2/KIR2DL3/
KIR2DS2 bind group 2 (C2) and group 1 (C1) HLA-C alleles,
respectively, whereas, KIR3DL1 recognizes HLA-Bw4 epitopes
[8–10]. Besides their role in inhibiting NK cell function,
combinations of KIR and HLA molecules also play an essential
role during NK education, to establish self-tolerance and to shape
the KIR repertoire of fully functional NK cells. Indeed functional
maturation of NK cells requires specific interaction with MHC
class I molecules [11]. However, MHC class I genes map to
chromosome 6 whereas KIR genes map to chromosome 19 [7].
Therefore, the inheritance of each group of genes and the
expression of the receptors and their ligands are physically
independent of one another. It has become increasingly clear that
the strength of KIR-HLA interactions has functional significance,
and can influence the susceptibility to or the outcome of various
infectious diseases, as previously shown for human immunodefi-
ciency virus type 1 (HIV-1) and hepatitis C virus (HCV) [12,13],
yet no such associations have been uncovered in the context of
CHIKV and DENV infections. Therefore, this study was
undertaken to determine the impact of inhibitory KIR and their
HLA-class I ligand genotype on the susceptibility to CHIKV and
DENV2 infections.

**Materials and Methods**

Ethics statement

The research we report here was conducted in accordance with
the principals expressed in the Declaration of Helsinki and was
approved by the relevant French and Gabonese institutional ethics
panels. Following the 2010 Gabon outbreak, the public-health
response was based on cooperation between the Gabonese
Ministry of Health (MoH) and “Centre International de
Recherches Médicales de Franceville” (CIRMF). All eligible
participants were aged ≥18 years provided informed consent,
but given the urgency of diagnosis and according to the MoH
directives; only individual oral consent was required for sampling.
All results were confidentially transmitted to the MoH. This
procedure was approved by an Institutional Review Board
(“Conseil Scientifique du CIRMF”) and the Regional Health
Director (Authorization N°139, May 27, 2010). The institutional
review board of the Pitié-Salpêtrière Hospital (Comité de

Protection des personnes, Ile-de-France, Paris, France) also
approved this study.

Study population

Peripheral blood samples from 73 CHIKV-infected (male: 44.7%; age mean: 37.5 yr), and 55 DENV-2-infected (male: 25.7%; age mean: 34.6 yr) patients were obtained between April and July 2010 during the simultaneous outbreak of CHIKV and DENV-2, which occurred in two provinces (Ogooue Lolo and Haut Ogooue) of southeast Gabon, occupied predominantly by the rural rainforest Kaningi population. Peripheral blood samples were collected on suspected adult cases during the first five days after the following symptoms: fever (>38.5°C), arthralgias, myalgias, headaches, rash, fatigue, nausea, vomiting, diarrhea or bleeding. Patients who met the case definition were sampled and tested for various arboviral RNA genomes, as described [4]. Each sample was negative for Yellow, West Nile and Rift Valley fevers, or malaria. As controls, 54 Gabonese healthy individuals were selected to match for origin, age (mean: 36.0 yr), and sex (male: 41%) [14]. This healthy control group was sampled between 2001 and 2007, before the first outbreak of CHIKV and DENV2, which occurred in Gabon from March 2007 [4,15].

Viral RNA extraction and quantification

Diagnosis for CHIKV or DENV fevers was confirmed and quantification performed using a standard quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) method. Briefly, RNA was extracted from 140 µL of plasma using the QIAamp Viral RNA Mini kit (Qiagen). cDNA was synthesized using qRT-PCR with a 9500 thermocycler (Applied biosystems), and mixing 25 µL of extracted RNA with 25 µL of High Capacity cDNA kit (Applied Biosystems). Five µL of newly synthesized cDNA was used as template in 25 µL of Taqman universal PCR Master Mix with specific CHIKV or DENV primers for a partial envelope (E1) gene sequence of CHIKV (692 bp, position 10 138–10829 nt) and a partial envelope (E) gene sequence of DENV-2 (758 bp, position 1503–2260 nt). Amplifications were run in duplicate in a 7500 Real-time PCR system (Applied Biosystem), as described [4,5].

KIR and HLA genotyping

DNA was extracted from whole blood using QIAamp DNA
blood mini kit (Qiagen). Inhibitory KIR genotyping was
performed by PCR using the KIR typing kit (Miltenyi Biotec,
Inc) following manufacturer's instructions, as previously performed
[14], and then confirmed by PCR using standard primers, and
internal controls, as previously described [16]. HLA-Class I alleles
were hybridized using LABType SSO kit (One Lambda). HLA
sequences were read with a LABScan 200 (Luminex Technology)
and computer-assisted HLA Fusion software.

Statistical analysis

Fisher's exact test was used to compare results between healthy
control and CHIKV⁺ or DENV⁺ patients. The P values of
statistically significant differences were then corrected, by the
formula Pⁿ = 1 - (1 - P)ⁿ, where n is the number of comparisons
[17].

**Results and Discussion**

We studied variations in KIR polymorphic CMH class I
genotypes and associations in CHIKV-, DENV2-infected patients
and healthy individuals from Gabon.
<table><caption>**Table 1.** Diversity of the KIR genotypes in CHIKV and DENV2-infected patients compared with healthy controls from the same origin.</caption><thead><tr><th rowspan="2">Genotype</th><th colspan="10">KIR</th><th colspan="2">CTRL (n=54)</th><th colspan="2">CHIKV<sup>+</sup> (n=30)</th><th colspan="2">DENV-2<sup>+</sup> (n=31)</th></tr><tr><th>2DL1</th><th>2DL2</th><th>2DL3</th><th>2DL4</th><th>2DL5</th><th>2DS1</th><th>2DS2</th><th>2DS3</th><th>2DS4</th><th>2DS5</th><th>3DL1</th><th>3DL2</th><th>3DL3</th><th>3DS1</th><th>3DP1</th><th>3DP2</th><th>n</th><th>%</th><th>n</th><th>%</th><th>p</th><th>n</th><th>%</th><th>p</th></tr></thead><tbody><tr><td>1</td><td>AA</td><td>+</td><td>-</td><td>+</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>13</td><td>24.0</td><td>2</td><td>6.7</td><td>5</td><td>16.1</td><td></td><td></td><td></td></tr><tr><td>2</td><td>AB/BB</td><td>+</td><td>-</td><td>+</td><td>+</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>3</td><td>5.6</td><td></td><td></td><td>1</td><td>3.2</td><td></td><td></td><td></td></tr><tr><td>3</td><td>AB/BB</td><td>+</td><td>-</td><td>+</td><td>+</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>2</td><td>3.7</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>4</td><td>AB/BB</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>1</td><td>1.8</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>5</td><td>AB/BB</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>-</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>3</td><td>5.6</td><td>2</td><td>6.7</td><td>1</td><td>3.2</td><td></td><td></td></tr><tr><td>6</td><td>AB/BB</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>2</td><td>3.7</td><td></td><td></td><td>2</td><td>6.4</td><td></td><td></td></tr><tr><td>7</td><td>AB/BB</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>1.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>8</td><td>AB/BB</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>1.8</td><td>1</td><td>3.3</td><td>1</td><td>3.2</td><td></td><td></td></tr><tr><td>9</td><td>AB/BB</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>1.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>10</td><td>AB/BB</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>2</td><td>3.7</td><td></td><td></td><td>1</td><td>3.2</td><td></td><td></td></tr><tr><td>11</td><td>AB/BB</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>1.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>12</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>3</td><td>5.6</td><td>1</td><td>3.3</td><td></td><td></td><td></td></tr><tr><td>13</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>3</td><td>5.6</td><td>1</td><td>3.3</td><td>2</td><td>6.4</td><td></td><td></td></tr><tr><td>14</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>3</td><td>5.6</td><td>2</td><td>6.7</td><td>2</td><td>6.4</td><td></td><td></td></tr><tr><td>15</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>11</td><td>20.3</td><td>0.006</td><td>1</td><td>3.2</td><td></td><td></td></tr><tr><td>16</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>2</td><td>1.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>17</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>2</td><td>3.7</td><td>2</td><td>6.7</td><td></td><td></td><td></td></tr><tr><td>18</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>1</td><td>1.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>19</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>1</td><td>3.3</td><td>1</td><td>3.2</td><td></td><td></td><td></td></tr><tr><td>20</td><td>AB/BB</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>3</td><td>10.0</td><td>0.043</td><td>6</td><td>19.3</td><td>0.001</td><td></td><td></td></tr><tr><td>21</td><td>AB/BB</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>1</td><td>3.3</td><td>1</td><td>3.2</td><td></td><td></td><td></td></tr><tr><td>22</td><td>AB/BB</td><td>-</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>3.3</td><td></td><td></td><td></td><td></td></tr><tr><td>23</td><td>AB/BB</td><td>-</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>3.3</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>24</td><td>AB/BB</td><td>-</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>2</td><td>6.7</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>25</td><td>AB/BB</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>-</td><td>-</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>3.3</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>26</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>3.3</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>27</td><td>AB/BB</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>-</td><td>-</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>2</td><td>6.7</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>28</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>2</td><td>6.7</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>29</td><td>AB/BB</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>3.3</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>30</td><td>AB/BB</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>1</td><td>3.3</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>31</td><td>AB/BB</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>3.3</td><td>1</td><td>3.2</td><td></td><td></td><td></td></tr><tr><td>32</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>3.3</td><td>1</td><td>3.2</td><td></td><td></td><td></td></tr><tr><td>33</td><td>AB/BB</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>1</td><td>3.2</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>
<table><caption>Table 1. Cont.</caption><thead><tr><th rowspan="2">Genotype</th><th colspan="2">KIR</th><th colspan="2">CTRL (n=54)</th><th colspan="2">CHIKV<sup>+</sup> (n=30)</th><th colspan="2">DENV-2<sup>+</sup> (n=31)</th></tr><tr><th>2DL1</th><th>2DL2</th><th>n</th><th>%</th><th>n</th><th>%</th><th>n</th><th>%</th></tr></thead><tbody><tr><td>34</td><td>AB/BB</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>1</td><td>3.2</td></tr><tr><td>35</td><td>AB/BB</td><td>+</td><td>—</td><td>—</td><td>+</td><td>+</td><td>1</td><td>3.2</td></tr><tr><td>36</td><td>AB/BB</td><td>+</td><td>—</td><td>—</td><td>+</td><td>+</td><td>1</td><td>3.2</td></tr><tr><td>37</td><td>AB/BB</td><td>+</td><td>—</td><td>—</td><td>+</td><td>+</td><td>1</td><td>3.2</td></tr></tbody></table>

doi:10.1371/journal.pone.0108798.t001

Initial analysis of the KIR locus among all participants identified 37 different genotypes [18,19]. Table 1 shows that the number of KIR genotypes in the different groups of patients varied from 18 to 21, with only KIR2DL4, KIR2DS4, KIR3DL3, KIR2DP1 and KIR3DP1 being detectable in all genotypes. All healthy and infected individuals possessed the framework genes (KIR2DL4, KIR3DL2 or KIR3DL3) [20]. This finding is biologically relevant to the studies showing that the NK cells lacking inhibitory receptors for self-MHC class I molecules could be hyporesponsive [21]. The frequency of individuals presenting an A/A genotype, containing only one activating gene (KIR2DS4), was higher in healthy individuals (24.0%) and DENV-2<sup>+</sup> samples (16.7%), compared to CHIKV<sup>+</sup> carriers (6.7%) (Table 1). The most represented AB/BB genotype in healthy donors (20.3%), genotype #15, was totally absent in CHIKV<sup>+</sup> patients (p = 0.006), and only present in 1/31 (3.2%) DENV-2<sup>+</sup> patient. Notably, in CHIKV<sup>+</sup> patients, each genotype was only poorly represented, and a large proportion of them were not observed in healthy donors. In addition, the frequency of genotype #20 was significantly higher in CHIKV<sup>+</sup> (p = 0.043) and DENV-2<sup>+</sup> (p = 0.001) patients than in healthy donors (Table 1). Altogether these data suggest that CHIKV and DENV infections were characterized by KIR distributions that differed from healthy controls, suggesting that the KIR repertoire could contribute to an increased susceptibility to CHIKV and/or DENV infection.

We next compared individual inhibitory KIR genotypes in healthy volunteers to patients infected with CHIKV or DENV2. Percentages of KIR gene carriers in the Gabonese control samples (Table 2) were in accordance to other African cohorts [22,23]. In DENV2-infected patients, proportions of all activating and inhibitory KIRs were similar to the healthy control. However, Beltram *et al.* [24] have recently shown for DENV-3 in southern Brazil significant differences for the KIR2DS1, KIR2DS5 and KIR2DL5 genes. The differences with our data could be explained by the DENV serotype (DENV-2 vs DENV-3) and the origin of the populations under study. In contrast, the proportion of KIR2DL1 gene carriers significantly decreased amongst CHIKV<sup>+</sup> (p<sup>n</sup> = 0.0338), compared to Gabonese healthy controls. Notably, amongst the “KIR and Diseases Database” (http://www.allelefrequencies.net/diseases/) several other diseases were reported to be significantly associated with a modulation of KIR2DL1, including placental Malaria in pregnant Kenyan women [25]. However, for CHIKV-infection, it is important to note that decreased frequency of KIR2DL1 gene is very consistent with the significant cell-surface phenotypic down-modulation of KIR2DL1 inversely associated with the viral load, that we have previously observed in acute CHIKV-infection [5]. Of note, the proportion of KIR2DS5 is significantly increased in CHIKV-infected patients (p<sup>n</sup> = 0.050) compared to healthy controls (Table 2), as previously observed in patients with HCV infection who cleared the virus in the association with a decreased of KIR2DL2/KIR2DS2 [26]. In addition, the presence of KIR2DS5 appears to be protective in ankylosing spondylitis, endometriosis and acute kidney graft rejection but a lack of KIR2DS5 and presence of C1 allotype was associated with rheumatoid arthritis [27]. KIR2DS5 code for surface receptor that trigger NK cell functions, although its ligand is unknown [28].

Since the interactions between KIR and their ligands are essential to control of NK cell function, we next evaluated the frequency of KIR genes in combination with the genes encoding their respective known ligands in the same patients. It is noteworthy that all Gabonese individuals, whatever their infectious status, had similar HLA-Bw4 genetic profiles (Figure 1A) which is consistent with what was observed in other African
<table><caption>**Table 2.** KIR genotypes and HLA ligand combinations in CHIV- and DENV2-infected patients, compared with healthy donors from the same Gabonese population.</caption><thead><tr><th rowspan="2"></th><th colspan="2">Control</th><th colspan="2">CHIKV<sup>+</sup></th><th colspan="2">DENV-2<sup>+</sup></th><th rowspan="2">n</th><th rowspan="2">%</th><th rowspan="2">p</th><th rowspan="2">p<sup>n</sup></th><th rowspan="2">p</th><th rowspan="2">p<sup>n</sup></th></tr><tr><th>n</th><th>%</th><th>n</th><th>%</th><th>p</th><th>p<sup>n</sup></th></tr></thead><tbody><tr><td colspan="13"><strong>Inhibitory KIR genotypes</strong></td></tr><tr><td>2DL1</td><td>54/54</td><td>100</td><td>63/73</td><td>86.1</td><td>0.0049</td><td>0.0338</td><td>52/52</td><td>100</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>2DL2</td><td>35/54</td><td>64.8</td><td>44/73</td><td>60.3</td><td>ns</td><td>ns</td><td>30/52</td><td>57.7</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>2DL3</td><td>43/54</td><td>79.6</td><td>48/73</td><td>65.7</td><td>ns</td><td>ns</td><td>41/52</td><td>78.8</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>2DL5</td><td>39/54</td><td>72.2</td><td>40/73</td><td>54.8</td><td>ns</td><td>ns</td><td>31/52</td><td>59.6</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>3DL1</td><td>54/54</td><td>100</td><td>73/75</td><td>97.3</td><td>ns</td><td>ns</td><td>47/50</td><td>94.0</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>3DL2</td><td>54/54</td><td>100</td><td>68/69</td><td>98.5</td><td>ns</td><td>ns</td><td>52/52</td><td>100</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>3DL3</td><td>54/54</td><td>100</td><td>69/69</td><td>100</td><td>ns</td><td>ns</td><td>52/52</td><td>100</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td colspan="13"><strong>Activating KIR genotypes</strong></td></tr><tr><td>2DL4</td><td>54/54</td><td>100</td><td>68/73</td><td>93.1</td><td>ns</td><td>ns</td><td>51/52</td><td>98.0</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>2DS1</td><td>10/54</td><td>18.5</td><td>11/55</td><td>20.0</td><td>ns</td><td>ns</td><td>15/52</td><td>28.8</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>2DS2</td><td>31/54</td><td>64.8</td><td>18/39</td><td>46.1</td><td>ns</td><td>ns</td><td>16/41</td><td>39.0</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>2DS3</td><td>19/54</td><td>79.6</td><td>7/36</td><td>19.4</td><td>0.0237</td><td>ns</td><td>6/36</td><td>16.7</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>2DS4</td><td>54/54</td><td>100</td><td>70/70</td><td>100</td><td>ns</td><td>ns</td><td>48/48</td><td>100</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>2DS5</td><td>18/54</td><td>33.3</td><td>33/56</td><td>58.9</td><td>0.0081</td><td>0.0489</td><td>23/52</td><td>44.2</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>3DS1</td><td>4/54</td><td>7.4</td><td>7/66</td><td>10.6</td><td>ns</td><td>ns</td><td>6/50</td><td>12.0</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td colspan="13"><strong>Inhibitory KIR-HLA associations</strong></td></tr><tr><td>C2<sup>+</sup> in 2DL1<sup>+</sup></td><td>32/47</td><td>68.1</td><td>44/48</td><td>91.6</td><td>0.0048</td><td>0.0238</td><td>26/40</td><td>65.0</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>C1<sup>+</sup> in 2DL2<sup>+</sup></td><td>20/31</td><td>64.5</td><td>21/33</td><td>63.4</td><td>ns</td><td>ns</td><td>14/22</td><td>63.6</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>C1<sup>+</sup> in 2DL3<sup>+</sup></td><td>27/38</td><td>71.0</td><td>18/40</td><td>45.0</td><td>ns</td><td>ns</td><td>21/31</td><td>67.7</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>C1<sup>+</sup> in 2DL2/2DL3<sup>+</sup></td><td>32/47</td><td>68.1</td><td>28/51</td><td>54.9</td><td>ns</td><td>ns</td><td>26/40</td><td>65.0</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>Bw4<sup>+</sup> in 3DL1<sup>+</sup></td><td>33/47</td><td>70.2</td><td>38/55</td><td>69.1</td><td>ns</td><td>ns</td><td>22/31</td><td>59.5</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td colspan="13"><strong>Inhibitory KIR3DL1<sup>+</sup>-HLA-Bw4 subtype associations</strong></td></tr><tr><td>Bw4-80Ile<sup>+</sup></td><td>22/47</td><td>46.8</td><td>38/55</td><td>69.1</td><td>0.0274</td><td>ns</td><td>20/37</td><td>54.0</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>Bw4-80Tm<sup>+</sup></td><td>12/47</td><td>25.5</td><td>1/55</td><td>1.8</td><td>0.0005</td><td>0.0011</td><td>3/37</td><td>8.1</td><td>0.0472</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td colspan="13"><strong>Activating KIR-HLA associations</strong></td></tr><tr><td>C2<sup>+</sup> in 2DS1<sup>+</sup></td><td>7/8</td><td>87.5</td><td>8/8</td><td>100</td><td>ns</td><td>ns</td><td>9/12</td><td>75.0</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>C1<sup>+</sup> in 2DS2<sup>+</sup></td><td>18/22</td><td>64.3</td><td>12/17</td><td>70.6</td><td>ns</td><td>ns</td><td>10/12</td><td>83.3</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td></tr></tbody></table>

P: Fisher exact test; P<sup>n</sup>: The P values of statistically significant differences were then corrected by the formula P<sup>n</sup> = 1 - (1 - P<sup>n</sup>), where n is the number of comparisons [17].
doi:10.1371/journal.pone.0108798.t002
<figure><img src="image_3.png" /><figcaption>**Figure 1. Allele frequency for HLA-B Bw4 (A) and HLA-C (B) subtypes in Gabonese individuals.** The frequency of each variable is shown for non-infected controls (n = 54; open bars), CHIKV-infected patients (n = 60; hatched bars), and DENV2-infected patients (n = 45; closed bars). \*P<0.05; \*\*P<0.001; \*\*\*P<0.0001.

doi:10.1371/journal.pone.0108798.g001</figcaption></figure>

cohorts [29]. However an increased frequency of HLA-B*44, an HLA-Bw4 allele, was recently associated with DENV3 severity in Brazilians [30]. This discrepancy suggests possible differences between the DENV serotypes and/or variations due to ethnicity. HLA-Bw4 (and not Bw6) allotypes serve as ligands for KIR3DL1 subtypes and subtypes are defined by amino-acid variations at positions 77-83 of the HLA-B molecules [7]. Table 2 shows similar proportions of HLA-Bw4 allele amongst KIR3DL1⁺ samples, whatever the study group. HLA-Bw4 molecules are further divided into two groups on the basis of whether isoleucine (Ile) or threonine (Thr) residues are present at position 80, defining HLA-Bw4-80Ile and Bw4-80Thr, respectively [31]. According to Norman et al. [32] an unusual KIR3DL1/S1 evolution occurred in Africans. Thus, KIR3DL1/S1 locus encodes two lineages of polymorphic inhibitory KIR3DL1 allotypes and one lineage of conserved activating KIR3DS1. They also highlighted that random combination of polymorphic KIR3DL1 receptor and HLA-B ligands has vast potential for varying the NK cell response to infection [32]. Figure 1A shows that Bw4-80Thr alleles are significantly more common in CHIKV⁺ patients than in both DENV2⁺ and healthy individuals, individuals. We examined the combination of Bw4-80Ile/Thr and KIR3DL1 in the context of sensitivity to CHIKV or DENV2 infection, and only observed significant modulation for the combination KIR3DL1:Bw4-80Thr (pⁿ = 0.001), compared to healthy controls (Table 2). In agreement

with receptor-binding and lysis-inhibition data suggesting that HLA-Bw4-80Ile molecules are more effective ligands for KIR3DL1 than HLA-Bw4-80Thr [33], we have observed no significant phenotypic modulation of KIR3DL1 expression after acute CHIKV [5] and DENV2 (Petitdemange *et al*., Manuscript in preparation) infections. In contrast, for HIV-1 the KIR3DL1:HLA-Bw4-80Ile combination was described in association with disease severity [34].

HLA-C molecules are also dichotomized into two groups, based on their KIR specificity; HLA-C group 1 (C1) specifically binds to KIR2DL2/DL3 and HLA-C group 2 (C2) binds to KIR2DL1 [8]. The genetic combinations of KIR2DL2/DL3 or KIR2DS2 and HLA-C1 genes remained similar in infected and healthy Gabonese yet we have previously reported a clonal expansion of NK cells that co-express activating CD94/NKG2C and inhibitory KIR2DL2/DL3 receptors in direct association with the viral load during acute CHIKV-infection [5]. The combination of KIR2DL2/DL3 with HLA-C1 might therefore not be involved in susceptibility to CHIKV infection but the observed expansion of NK cells expressing these receptors suggests that this interaction is of importance during the development of the disease. For example, KIR2DL2/DL3:HLA-C1 interaction could be associated with the delayed progression to the development of persistent chronic inflammation in CHIKV-infected patients. Infiltrating activated NK cells were found in synovial tissue in close vicinity to
chronically CHIKV-infected perivascular synovial macrophages [35]. Importantly, a significant increase in frequency of HLA-C2 was observed in CHIKV-infected patients (p = 0.0041), mainly of HLA-C2 homozygous subjects, compared to DENV+ patients and controls (Figure 1B). More intriguingly, this HLA-C2 increased effect was also significantly observed in combination with KIR2DL1 (p = 0.0238) (Table 2). In this regard, however, it cannot be ruled out that these results were influenced by population demographic history; these results will need to be confirmed through the study of samples collected from other ethnic groups. Notably, this data highlights that CHIKV infection could be influenced by KIR2DL1/HLA-C2 interplay. Consistent with this notion we have previously shown a depletion of KIR2DL1+ cells early after CHIKV infection, inversely associated with the viral load [5].

The finding that inhibitory interactions are protective against a
viral infection initially seems counterintuitive. However, NK cells
are held in check by their inhibitory receptors as originally
proposed by the missing-self hypothesis' and loss of these
interactions could be a key mechanism to allow NK cell activation
[36]. *In vitro* studies with autologous influenza infected targets
have shown that NK cells from individuals with KIR2DL3:HLA-
C1 were activated more rapidly than those with KIR2DL1:HLA-
C2 [37]. Consistently we previously showed that the KIR2DL1+
NK cell depletion was associated with an expansion of KIR2DL2/

DL3+ NKG2C+ cells after acute CHIKV infection [5]. In summary, we can hypothesize that the expansion of highly functional NK cells and the development of a strong adaptive memory response, as previously described [5,38], are independent of a specific KIR/HLA pathway in DENV2 infection, but certainly associated to an interplay between KIR2DL1 and HLA-C2 in response to CHIKV infection. This study is an interesting first step towards understanding the different roles of KIR and their specific ligands in CHIKV and DENV2 infections. However, further studies will be necessary to conclude as to the role of these receptors and ligands in the context of susceptibility to these infections or in the development of the disease and chronic or hemorrhagic symptoms.

Acknowledgments

We thank Philippe Engandja from CIRMF (Franceville, Gabon) for
technical assistance.

Author Contributions

Conceived and designed the experiments: CP EL VV. Performed the experiments: CP NW JMJ. Analyzed the data: CP NW IT EL VV. Contributed reagents/materials/analysis tools: NW EL. Wrote the paper: CP NW VV.

References

1. Pialoux G, Gauzere BA, Jaureguiberry S, Strobel M (2007) Chikungunya, an epidemic arbovirus. Lancet Infect Dis 7: 319-327.

2. World Health Organization. Fact sheet no. 117: dengue and dengue haemorrhagic fever. Available: http://www.who.int/mediacentre/factsheets/ fs117/en/. Accessed 2009.

3. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srikiatkhachorn A, et al. (2010) Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Tro Dis 4: e617.

4. Caron M, Paupy C, Grard G, Becquart P, Mombo I, et al. (2012) Recent introduction and rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated with human and mosquito coinfections in Gabon, central Africa. Clin Infect Dis 55: e45-53.

5. Petitdemange C, Becquart P, Wauquier N, Béziat V, Debré P, et al. (2011) Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog 7: e1002268.

6. Azeredo EL, De Oliveira-Pinto LM, Zagne SM, Cerqueira DI, Nogueira RM, et al. (2006) NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease. Clin Exp Immunol 143: 345-356.

7. Kulkarni S, Martin MP, Carrington M (2008) The Yin and Yang of HLA and KIR in human disease. Semin Immunol 20: 343-352.

8. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23: 225-274.

9. Falco M, Moretta L, Moretta A, Bottino C (2013) KIR and KIR ligand polymorphism: a new area for clinical applications? Tissue Antigens 82: 363-373.

10. Ivarsson MA, Michaëlsson J, Fauriat C (2014) Activating killer cell Ig-like receptors in health and disease. Front Immunol 5:184.

11. Anfossi N, André P, Guia S, Falk CS, Roetynck S, et al. (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity 25: 331-342.

12. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, et al. (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305: 872-874.

13. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, et al. (2007) Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Gen 39: 733-740.

14. Wauquier N, Padilla C, Becquart P, Leroy E, Vieillard V (2010) Association of KIR2DS1 and KIR2DS3 with fatal outcome in Ebola virus infection. Immunogenetics 62: 767-771.

15. Leroy EM, Nkoghe D, Ollomo B, Nze-Nkoghe C, Becquart P, et al. (2009) Concurrent chikungunya and dengue virus infections during simultaneous outbreaks, Gabon, 2007. Emerg Infect Dis 15: 591-593.

16. Vilches C, Castaño J, Gómez-Lozano N, Estefania E (2007) Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens 70: 415-422.

17. Svejgaard A, Ryder LP (1994) HLA and disease associations: detecting the strongest association. Tissue Antigens 43: 18-27.

18. Martin MP, Single RM, Wilson MJ, Trowsdale J, Carrington M (2009) KIR haplotypes defined by segregation analysis in 59 Centre d'Etude Polymorphisme Humain (CEPH) families. Immunogenetics 61: 79.

19. Hollenbach JA, Nocedal I, Ladner MB, Single RM, Trachtenberg EA (2012) Killer cell immunoglobulin-like receptor (KIR) gene content variation in the HGDP-CEPH populations. Immunogenetics 64: 719-737.

20. Vilches C, Parham P (2002) KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 20: 217-251.

21. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, et al. (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709-713.

22. Norman PJ, Carrington CV, Byng M, Maxwell LD, Curran MD, et al. (2002) Natural killer cell immunoglobulin-like receptor (KIR) locus profiles in African and South Asian populations. Genes Immunol 3: 86-95.

23. Denis L, Sivula J, Gourraud PA, Kerdudou N, Chout R, et al. (2005) Genetic diversity of KIR natural killer cell markers in populations from France, Guadeloupe, Finland, Senegal and Réunion. Tissue Antigens 66: 267-276.

24. Beltrame LM, Sell AM, Moliterno RA, Clementino SL, Cardozo DM, et al. (2013) Influence of KIR genes and their HLA ligands in susceptibility to dengue in a population from southern Brazil. Tissue Antigens 82: 397-404.

25. Osomun YO, Blackstock AJ, Gatei W, Hightower A, van Eijk AM, et al. (2012) Differential association of gene content polymorphisms of killer cell immunoglobulin-like receptors with placental malaria in HIV- and HIV+ mothers. PLoS One 7: e38617.

26. Paladino N, Flores AC, Marcos CY, Fainboim H, Theiler G, et al. (2007) Increased frequencies of activating natural killer receptors are associated with liver injury in individuals who do not eliminate hepatitis C virus. Tissue Antigens 69:109-111.

27. Nowak I, Majorczyk E, Wiśniewski A, Pawlik A, Magott-Procelewska M, et al. (2010) Does the KIR2DS5 gene protect from some human diseases? PLoS One 5: e12381.

28. Della Chiesa M, Romeo E, Falco M, Balsamo M, Augugliaro R, et al. (2008) Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function. Eur J Immunol 38: 2284-2289.

29. Paximadis M, Mathebula TY, Gentle NL, Vardas E, Colvin M, et al. (2012) Human leukocyte antigen class I (A, B, C) and II (DRB1) diversity in the black and Caucasian South African population. Hum Immunol 73: 80-92.

30. Xavier Eurico de Alencar L, de Mendonça Braga-Neto U, José Moura do Nascimento E, Tenório Cordeiro M, Maria Silva A, et al. (2013) HLA-B*44 is associated with Dengue severity caused by DENV-3 in a Brazilian population. J Trop Med 2013: 648475.

31. Müller CA, Engler-Blum G, Gekeler V, Steiert I, Weiss E, et al. (1989) Genetic and serological heterogeneity of the supertypic HLA-B locus specificities Bw4 and Bw6. Immunogenetics 30: 200-207.

32. Norman PJ, Abi-Rached L, Gendzekhadze K, Korbel D, Gleimer M, et al. (2007) Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat Genet 39: 1092-1099.
33. Carr WH, Pando MJ, Parham P (2005) KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol 175: 5222-5229.

34. Parham P (2005) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5: 201-214.

35. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, et al. (2010) Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 184: 5914-5927.

36. Ljunggren HG, Kärre K (1990) In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 11: 237-244.

37. Ahlenstiel G, Martin MP, Gao X, Carrington M, Rehermann B (2008) Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest 118: 1017-1026.

38. Wauquier N, Becquart P, Nkoghe D, Padilla C, Ndjoyi-Mbiguino A, et al. (2011) The acute phase of Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J Infect Dis 204: 115-123.